Sarcopenia in chronic kidney disease: from bench to bedside

키워드

참고문헌 (233)

1. 최경묵, "Sarcopenia and Sarcopenic Obesity", Endocrinology and Metabolism, 28(2), pp.86~89 (2013), 대한내분비학회
2. Rosenberg IH, "Sarcopenia : origins and clinical relevance", J Nutr, 127(5 Suppl), pp.990S~991S (1997)
3. Cruz-Jentoft AJ, "Sarcopenia : revised European consensus on definition and diagnosis", Age Ageing, 48, pp.601~ (2019)
4. Hyungchul Park, "Sarcopenia is associated with severe erectile dysfunction in older adults: a population-based cohort study", The Korean Journal of Internal Medicine, 35(5), pp.1245~1253 (2020), 대한내과학회[DOI]
5. Der Sheng Sun, "The impact of sarcopenia on health-related quality of life in elderly people: Korean National Health and Nutrition Examination Survey", The Korean Journal of Internal Medicine, 34(4), pp.877~884 (2019), 대한내과학회[DOI]
6. Min Cheol Kim, "Prevalence and associated risk of advanced colorectal neoplasia in adults with sarcopenia", The Korean Journal of Internal Medicine, 37(2), pp.294~303 (2022), 대한내과학회[DOI]
7. Sabatino A, "Sarcopenia in chronic kidney disease : what have we learned so far?", J Nephrol, 34, pp.1347~1372 (2021)
8. Carrero JJ, "Global prevalence of protein-energy wasting in kidney disease : a meta-analysis of contemporary observational studies from the international society of renal nutrition and metabolism", J Ren Nutr, 28, pp.380~392 (2018)
9. Cruz-Jentoft AJ, "Sarcopenia : European consensus on definition and diagnosis : report of the European Working Group on sarcopenia in older people", Age Ageing, 39, pp.412~423 (2010)
10. Pereira RA, "Sarcopenia in chronic kidney disease on conservative therapy : prevalence and association with mortality", Nephrol Dial Transplant, 30, pp.1718~1725 (2015)
11. Vettoretti S, "Sarcopenia is associated with malnutrition but not with systemic inflammation in older persons with advanced CKD", Nutrients, 11, pp.1378~ (2019)
12. Ren H, "Sarcopenia in patients undergoing maintenance hemodialysis : incidence rate, risk factors and its effect on survival risk", Ren Fail, 38, pp.364~371 (2016)
13. Hotta C, "Relation of physical function and physical activity to sarcopenia in hemodialysis patients : a preliminary study", Int J Cardiol, 191, pp.198~200 (2015)
14. da Silva MZC, "Update of the European consensus on sarcopenia : what has changed in diagnosis and prevalence in peritoneal dialysis?", Eur J Clin Nutr, 73, pp.1209~1211 (2019)
15. Abro A, "Differences in the prevalence of sarcopenia in peritoneal dialysis patients using hand grip strength and appendicular lean mass : depends upon guideline definitions", Eur J Clin Nutr, 72, pp.993~999 (2018)
16. Souza VA, "Sarcopenia in patients with chronic kidney disease not yet on dialysis : analysis of the prevalence and associated factors", PLoS One, 12, pp.e0176230~ (2017)
17. 손형은, "The importance of muscle mass in predicting intradialytic hypotension in patients undergoing maintenance hemodialysis", Kidney Research and Clinical Practice, 41(5), pp.611~622 (2022), 대한신장학회[DOI]
18. Kamijo Y, "Sarcopenia and frailty in PD : impact on mortality, malnutrition, and inflammation", Perit Dial Int, 38, pp.447~454 (2018)
19. Mori K, "Impact of diabetes on sarcopenia and mortality in patients undergoing hemodialysis", BMC Nephrol, 20, pp.105~ (2019)
20. Kittiskulnam P, "Sarcopenia and its individual criteria are associated, in part, with mortality among patients on hemodialysis", Kidney Int, 92, pp.238~247 (2017)
21. 강석휘, "Association of sarcopenia and its components with clinical outcomes in patients undergoing peritoneal dialysis", Kidney Research and Clinical Practice, 41(6), pp.741~752 (2022), 대한신장학회[DOI]
22. 김좌경, "Impact of sarcopenia on long-term mortality and cardiovascular events in patients undergoing hemodialysis", The Korean Journal of Internal Medicine, 34(3), pp.599~607 (2019), 대한내과학회[DOI]
23. Hadi Tabibi, "Prevalence of dynapenic obesity and sarcopenic obesity and their associations with cardiovascular disease risk factors in peritoneal dialysis patients", Kidney Research and Clinical Practice, 37(4), pp.404~413 (2018), 대한신장학회
24. Isoyama N, "Comparative associations of muscle mass and muscle strength with mortality in dialysis patients", Clin J Am Soc Nephrol, 9, pp.1720~1728 (2014)
25. Kim JK, "Prevalence of and factors associated with sarcopenia in elderly patients with end-stage renal disease", Clin Nutr, 33, pp.64~68 (2014)
26. Lin YL, "Decreased serum fatty acid binding protein 4 concentrations are associated with sarcopenia in chronic hemodialysis patients", Clin Chim Acta, 485, pp.113~118 (2018)
27. Ishikawa S, "Loop diuretics are associated with greater risk of sarcopenia in patients with non-dialysis-dependent chronic kidney disease", PLoS One, 13, pp.e0192990~ (2018)
28. Bataille S, "The diagnosis of sarcopenia is mainly driven by muscle mass in hemodialysis patients", Clin Nutr, 36, pp.1654~1660 (2017)
29. Silva Maryanne Zilli Canedo, "Age, diabetes mellitus, and dialysis modality are associated with risk of poor muscle strength and physical function in hemodialysis and peritoneal dialysis patients", Kidney Research and Clinical Practice, 40(2), pp.294~303 (2021), 대한신장학회[DOI]
30. As’habi A, "Prevalence of sarcopenia and dynapenia and their determinants in Iranian peritoneal dialysis patients", Iran J Kidney Dis, 12, pp.53~60 (2018)
31. Lopes LCC, "Intradialytic resistance training improves functional capacity and lean mass gain in individuals on hemodialysis : a randomized pilot trial", Arch Phys Med Rehabil, 100, pp.2151~2158 (2019)
32. Dong ZJ, "Effects of intradialytic resistance exercise on systemic inflammation in maintenance hemodialysis patients with sarcopenia : a randomized controlled trial", Int Urol Nephrol, 51, pp.1415~1424 (2019)
33. Zhou Y, "Muscle mass and plasma myostatin after exercise training : a substudy of Renal Exercise(RENEXC)-a randomized controlled trial", Nephrol Dial Transplant, 36, pp.95~103 (2021)
34. Koh KP, "Effect of intradialytic versus home-based aerobic exercise training on physical function and vascular parameters in hemodialysis patients : a randomized pilot study", Am J Kidney Dis, 55, pp.88~99 (2010)
35. Allman MA, "Energy supplementation and the nutritional status of hemodialysis patients", Am J Clin Nutr, 51, pp.558~562 (1990)
36. Eustace JA, "Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia", Kidney Int, 57, pp.2527~2538 (2000)
37. Hiroshige K, "Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic haemodialysis", Nephrol Dial Transplant, 16, pp.1856~1862 (2001)
38. Zilles M, "How to prevent renal cachexia? A clinical randomized pilot study testing oral supplemental nutrition in hemodialysis patients with and without human immunodeficiency virus infection", J Ren Nutr, 28, pp.37~44 (2018)
39. Pupim LB, "Intradialytic oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status", J Am Soc Nephrol, 17, pp.3149~3157 (2006)
40. de Brito-Ashurst I, "Bicarbonate supplementation slows progression of CKD and improves nutritional status", J Am Soc Nephrol, 20, pp.2075~2084 (2009)
41. Stein A, "Role of an improvement in acid-base status and nutrition in CAPD patients", Kidney Int, 52, pp.1089~1095 (1997)
42. Stenvinkel P, "Muscle wasting in end-stage renal disease promulgates premature death : established, emerging and potential novel treatment strategies", Nephrol Dial Transplant, 31, pp.1070~1077 (2016)
43. Bailey JL, "The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway", J Clin Invest, 97, pp.1447~1453 (1996)
44. Wang XH, "Exercise ameliorates chronic kidney disease-induced defects in muscle protein metabolism and progenitor cell function", Kidney Int, 76, pp.751~759 (2009)
45. Adey D, "Reduced synthesis of muscle proteins in chronic renal failure", Am J Physiol Endocrinol Metab, 278, pp.E219~E225 (2000)
46. Deger SM, "Systemic inflammation is associated with exaggerated skeletal muscle protein catabolism in maintenance hemodialysis patients", JCI Insight, 2, pp.e95185~ (2017)
47. Garibotto G, "Insulin sensitivity of muscle protein metabolism is altered in patients with chronic kidney disease and metabolic acidosis", Kidney Int, 88, pp.1419~1426 (2015)
48. Raj DS, "Coordinated increase in albumin, fibrinogen, and muscle protein synthesis during hemodialysis : role of cytokines", Am J Physiol Endocrinol Metab, 286, pp.E658~E664 (2004)
49. van Vliet S, "Dysregulated handling of dietary protein and muscle protein synthesis after mixed-meal ingestion in maintenance hemodialysis patients", Kidney Int Rep, 3, pp.1403~1415 (2018)
50. May RC, "Mechanisms for defects in muscle protein metabolism in rats with chronic uremia. Influence of metabolic acidosis", J Clin Invest, 79, pp.1099~1103 (1987)
51. Wang XH, "Mechanisms of muscle wasting in chronic kidney disease", Nat Rev Nephrol, 10, pp.504~516 (2014)
52. Bodine SC, "Identification of ubiquitin ligases required for skeletal muscle atrophy", Science, 294, pp.1704~1708 (2001)
53. Stitt TN, "The IGF-1", PI3K, Mol Cell, pp.2004, 14[DOI]
54. Lai KM, "Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy", Mol Cell Biol, 24, pp.9295~9304 (2004)
55. Bonaldo P, "Cellular and molecular mechanisms of muscle atrophy", Dis Model Mech, 6, pp.25~39 (2013)
56. Lee SW, "Regulation of muscle protein degradation : coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase", J Am Soc Nephrol, 15, pp.1537~1545 (2004)
57. Sandri M, "Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1and cause skeletal muscle atrophy", Cell, 117, pp.399~412 (2004)
58. Morley JE, "Hormones and sarcopenia", Curr Pharm Des, 23, pp.4484~4492 (2017)
59. White JP, "Testosterone regulation of Akt", mTORC1, Mol Cell Endocrinol, pp.2013, 365[DOI]
60. Johansen KL, "US renal data system 2020 annual data report : epidemiology of kidney disease in the United States", Am J Kidney Dis, 77(4Suppl 1), pp.A7~A8 (2021)
61. 홍유아, "Trends in epidemiologic characteristics of end-stage renal disease from 2019 Korean Renal Data System (KORDS)", Kidney Research and Clinical Practice, 40(1), pp.52~61 (2021), 대한신장학회[DOI]
62. 진동찬, "Current characteristics of dialysis therapy in Korea: 2016 registry data focusing on diabetic patients", Kidney Research and Clinical Practice, 37(1), pp.20~29 (2018), 대한신장학회
63. Kim TN, "Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes : the Korean Sarcopenic Obesity Study(KSOS)", Diabetes Care, 33, pp.1497~1499 (2010)
64. Huang YM, "Sarcopenia is an independent risk factor for severe diabetic nephropathy in type 2 diabetes : a long-term follow-up propensity score-matched diabetes cohort study", J Clin Med, 11, pp.2992~ (2022)
65. Abbatecola AM, "Insulin resistance and muscle strength in older persons", J Gerontol A Biol Sci Med Sci, 60, pp.1278~1282 (2005)
66. Abbatecola AM, "Is there a relationship between insulin resistance and frailty syndrome?", Curr Pharm Des, 14, pp.405~410 (2008)
67. Mori H, "Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes", J Diabetes Investig, 10, pp.1332~1340 (2019)
68. Yokota T, "Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome", J Diabetes Investig, 8, pp.535~541 (2017)
69. Sato H, "Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice", Diabetologia, 59, pp.2426~2434 (2016)
70. Skov V, "Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome", PLoS One, 3, pp.e2466~ (2008)
71. Chai W, "Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism", Diabetes, 61, pp.888~896 (2012)
72. Giannocco G, "Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats", Eur J Pharmacol, 698, pp.74~86 (2013)
73. Holmes BF, "Chronic activation of 5’-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle", J Appl Physiol(1985), 87, pp.1990~1995 (1999)
74. Pawelczyk L, "Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome", Eur J Obstet Gynecol Reprod Biol, 113, pp.209~213 (2004)
75. Hernández-Álvarez D, "Long-term moderate exercise combined with metformin treatment induces an hormetic response that prevents strength and muscle mass loss in old female wistar rats", Oxid Med Cell Longev, 2019, pp.3428543~ (2019)
76. Walton RG, "Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults : a randomized, double-blind, placebo-controlled, multicenter trial : the MASTERS trial", Aging Cell, 18, pp.e13039~ (2019)
77. Das S, "Effect of metformin on exercise capacity : a meta-analysis", Diabetes Res Clin Pract, 144, pp.270~278 (2018)
78. Dousdampanis P, "Role of testosterone in the pathogenesis, progression, prognosis and comorbidity of men with chronic kidney disease", Ther Apher Dial, 18, pp.220~230 (2014)
79. Leavey SF, "Endocrine abnormalities in chronic renal failure", Endocrinol Metab Clin North Am, 31, pp.107~119 (2002)
80. Palmer BF, "Sexual dysfunction in uremia", J Am Soc Nephrol, 10, pp.1381~1388 (1999)
81. Serra C, "Testosterone improves the regeneration of old and young mouse skeletal muscle", J Gerontol A Biol Sci Med Sci, 68, pp.17~26 (2013)
82. Axell AM, "Continuous testosterone administration prevents skeletal muscle atrophy and enhances resistance to fatigue in orchidectomized male mice", Am J Physiol Endocrinol Metab, 291, pp.E506~E516 (2006)
83. LeBrasseur NK, "Effects of testosterone therapy on muscle performance and physical function in older men with mobility limitations(the TOM trial) : design and methods", Contemp Clin Trials, 30, pp.133~140 (2009)
84. Bhasin S, "Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations : secondary analyses of the testosterone trials", Lancet Diabetes Endocrinol, 6, pp.879~890 (2018)
85. Dias JP, "Effects of transdermal testosterone gel or an aromatase inhibitor on serum concentration and pulsatility of growth hormone in older men with age-related low testosterone", Metabolism, 69, pp.143~147 (2017)
86. O’Connell MD, "Do the effects of testosterone on muscle strength, physical function, body composition, and quality of life persist six months after treatment in intermediate-frail and frail elderly men?", J Clin Endocrinol Metab, 96, pp.454~458 (2011)
87. Dias JP, "Effects of transdermal testosterone gel or an aromatase inhibitor on prostate volume in older men", J Clin Endocrinol Metab, 101, pp.1865~1871 (2016)
88. Corona G, "Injectable testosterone undecanoate for the treatment of hypogonadism", Expert Opin Pharmacother, 15, pp.1903~1926 (2014)
89. Christiansen AR, "Selective androgen receptor modulators: the future of androgen therapy?", Transl Androl Urol, 9(Suppl 2), pp.S135~S148 (2020)
90. Papanicolaou DA, "A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator(SARM), MK-0773 in female participants with sarcopenia", J Nutr Health Aging, 17, pp.533~543 (2013)
91. Dalton JT, "The selective androgen receptor modulator GTx-024(enobosarm)improves lean body mass and physical function in healthy elderly men and postmenopausal women : results of a double-blind, placebo-controlled phase II trial", J Cachexia Sarcopenia Muscle, 2, pp.153~161 (2011)
92. Crawford J, "Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients(POWER trials)", Curr Oncol Rep, 18, pp.37~ (2016)
93. Dalton JT, "The long and winding road for selective androgen receptor modulators", Br J Clin Pharmacol, 83, pp.2131~2133 (2017)
94. Saxton RA, "mTOR signaling in growth, metabolism, and disease", Cell, 168, pp.960~976 (2017)
95. Bodine SC, "Akt", mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo, 2001, pp.3, 1014~1019
96. Deblon N, "Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats", Br J Pharmacol, 165, pp.2325~2340 (2012)
97. Gyawali B, "Muscle wasting associated with the long-term use of mTOR inhibitors", Mol Clin Oncol, 5, pp.641~646 (2016)
98. Chrienova Z, "The role of mTOR in age-related diseases", J Enzyme Inhib Med Chem, 36, pp.1678~1692 (2021)
99. Ramos FJ, "Rapamycin reverses elevated mTORC1 signaling in lamin A", C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival, 2012, pp.4, 144ra103~
100. Gui Y, "mTOR signaling in kidney diseases", Kidney360, 1, pp.1319~1327 (2020)
101. Garlick PJ, "Amino acid infusion increases the sensitivity of muscle protein synthesis in vivo to insulin. Effect of branched-chain amino acids", Biochem J, 254, pp.579~584 (1988)
102. Li JB, "Influence of amino acid availability on protein turnover in perfused skeletal muscle", Biochim Biophys Acta, 544, pp.351~359 (1978)
103. Buse MG, "Leucine. A possible regulator of protein turnover in muscle", J Clin Invest, 56, pp.1250~1261 (1975)
104. Anthony JC, "Leucine stimulates translation initiation in skeletal muscle of postabsorptive rats via a rapamycin-sensitive pathway", J Nutr, 130, pp.2413~2419 (2000)
105. Anthony JC, "Orally administered leucine enhances protein synthesis in skeletal muscle of diabetic rats in the absence of increases in 4E-BP1 or S6K1 phosphorylation", Diabetes, 51, pp.928~936 (2002)
106. Grodstein GP, "Nutritional and metabolic response to catabolic stress in uremia", Am J Clin Nutr, 33, pp.1411~1416 (1980)
107. Kalantar-Zadeh K, "Poor nutritional status and inflammation : metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure", Semin Dial, 17, pp.455~465 (2004)
108. Pickering WP, "Nutrition in CAPD : serum bicarbonate and the ubiquitin-proteasome system in muscle", Kidney Int, 61, pp.1286~1292 (2002)
109. Wolfson M, "Amino acid losses during hemodialysis with infusion of amino acids and glucose", Kidney Int, 21, pp.500~506 (1982)
110. Ikizler TA, "Amino acid and albumin losses during hemodialysis", Kidney Int, 46, pp.830~837 (1994)
111. Chazot C, "Dialytic nutrition : provision of amino acids in dialysate during hemodialysis", Kidney Int, 52, pp.1663~1670 (1997)
112. Mak RH, "Insulin resistance but IGF-I sensitivity in chronic renal failure", Am J Physiol, 271(1 Pt 2), pp.F114~F119 (1996)
113. Gupta V, "Growth hormone in chronic renal disease", Indian J Endocrinol Metab, 16, pp.195~203 (2012)
114. Fouque D, "Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients", Kidney Int, 57, pp.646~654 (2000)
115. Kopple JD, "Does parathyroid hormone cause protein wasting?", Contrib Nephrol, 20, pp.138~148 (1980)
116. Fouque D, "A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease", Kidney Int, 73, pp.391~398 (2008)
117. Ikizler TA, "KDOQI clinical practice guideline for nutrition in CKD : 2020 update", Am J Kidney Dis, 76(3 Suppl 1), pp.S1~S107 (2020)
118. Haba Y, "Effect of oral branchedchain amino acids and glutamine supplementation on skeletal muscle atrophy after total gastrectomy in rat model", J Surg Res, 243, pp.281~288 (2019)
119. Baptista IL, "Leucine and HMB differentially modulate proteasome system in skeletal muscle under different sarcopenic conditions", PLoS One, 8, pp.e76752~ (2013)
120. Bai GH, "Effects of branched-chain amino acid-rich supplementation on EWGSOP2criteria for sarcopenia in older adults : a systematic review and meta-analysis", Eur J Nutr, 61, pp.637~651 (2022)
121. Gielen E, "Nutritional interventions to improve muscle mass, muscle strength, and physical performance in older people : an umbrella review of systematic reviews and meta-analyses", Nutr Rev, 79, pp.121~147 (2021)
122. Acchiardo S, "Effect of essential amino acids(EAA)on chronic hemodialysis(CHD)patients(PTS)", Trans Am Soc Artif Intern Organs, 28, pp.608~614 (1982)
123. Wu H, "Effect of beta-hydroxy-beta-methylbutyrate supplementation on muscle loss in older adults : a systematic review and meta-analysis", Arch Gerontol Geriatr, 61, pp.168~175 (2015)
124. Gumucio JP, "Atrogin-1, MuRF-1, and sarcopenia", Endocrine, 43, pp.12~21 (2013)
125. Cohen S, "Muscle wasting in disease : molecular mechanisms and promising therapies", Nat Rev Drug Discov, 14, pp.58~74 (2015)
126. Du J, "Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions", J Clin Invest, 113, pp.115~123 (2004)
127. Workeneh BT, "Development of a diagnostic method for detecting increased muscle protein degradation in patients with catabolic conditions", J Am Soc Nephrol, 17, pp.3233~3239 (2006)
128. Elkasrawy MN, "Myostatin(GDF-8)as a key factor linking muscle mass and bone structure", J Musculoskelet Neuronal Interact, 10, pp.56~63 (2010)
129. Han HQ, "Myostatin", activin pathway antagonism : molecular basis and therapeutic potential, 2013, pp.45, 2333~2347
130. Walker RG, "Biochemistry and biology of GDF11 and myostatin : similarities, differences, and questions for future investigation", Circ Res, 118, pp.1125~1142 (2016)
131. Trendelenburg AU, "Myostatin reduces Akt", TORC1, Am J Physiol Cell Physiol, pp.2009, 296[DOI]
132. Argilés JM, "Myostatin : more than just a regulator of muscle mass", Drug Discov Today, 17, pp.702~709 (2012)
133. Feike Y, "Advances in research on pharmacotherapy of sarcopenia", Aging Med(Milton), 4, pp.221~233 (2021)
134. Yano S, "Relationship between blood myostatin levels and kidney function : shimane CoHRE study", PLoS One, 10, pp.e0141035~ (2015)
135. Verzola D, "Apoptosis and myostatin mRNA are upregulated in the skeletal muscle of patients with chronic kidney disease", Kidney Int, 79, pp.773~782 (2011)
136. Price SR, "Muscle atrophy in chronic kidney disease results from abnormalities in insulin signaling", J Ren Nutr, 20(5 Suppl), pp.S24~S28 (2010)
137. Zhang L, "Stat3 activation links a C", EBPδto myostatin pathway to stimulate loss of muscle mass, 2013, pp.18, 368~379
138. Becker C, "Myostatin antibody(LY2495655)in older weak fallers : a proof-of-concept, randomised, phase 2 trial", Lancet Diabetes Endocrinol, 3, pp.948~957 (2015)
139. Wagner KR, "A phase I", IItrial of MYO-029 in adult subjects with muscular dystrophy, 2008, pp.63, 561~571
140. Morvan F, "Blockade of activin type II receptors with a dual anti-ActRIIA", IIB antibody is critical to promote maximal skeletal muscle hypertrophy, 2017, pp.114, 12448~12453
141. Lach-Trifilieff E, "An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy", Mol Cell Biol, 34, pp.606~618 (2014)
142. Rooks D, "Treatment of sarcopenia with bimagrumab : results from a phase II, randomized, controlled, proof-of-concept study", J Am Geriatr Soc, 65, pp.1988~1995 (2017)
143. Rooks D, "Bimagrumab vs optimized standard of care for treatment of sarcopenia in community-dwelling older adults : a randomized clinical trial", JAMA Netw Open, 3, pp.e2020836~ (2020)
144. Heymsfield SB, "Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity : a phase 2 randomized clinical trial", JAMA Netw Open, 4, pp.e2033457~ (2021)
145. Cadena SM, "Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type", J Appl Physiol(1985), 109, pp.635~642 (2010)
146. Campbell C, "Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy : results of a randomized, placebo-controlled clinical trial", Muscle Nerve, 55, pp.458~464 (2017)
147. Castonguay R, "Follistatin-288-Fc fusion protein promotes localized growth of skeletal muscle", J Pharmacol Exp Ther, 368, pp.435~445 (2019)
148. Ozawa T, "Systemic administration of monovalent follistatin-like 3-Fc-fusion protein increases muscle mass in mice", iScience, 24, pp.102488~ (2021)
149. Pearsall RS, "Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease", Sci Rep, 9, pp.11392~ (2019)
150. Statland JM, "Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy", Muscle Nerve, 66, pp.50~62 (2022)
151. Giesige CR, "AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD", JCI Insight, 3, pp.e123538~ (2018)
152. Mendell JR, "Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes", Mol Ther, 25, pp.870~879 (2017)
153. Al-Zaidy SA, "Follistatin gene therapy improves ambulation in Becker muscular dystrophy", J Neuromuscul Dis, 2, pp.185~192 (2015)
154. Mendell JR, "A phase 1", 2a follistatin gene therapy trial for becker muscular dystrophy, 2015, pp.23, 192~201
155. Ravarotto Verdiana, "Pathomechanism of oxidative stress in cardiovascularrenal remodeling and therapeutic strategies", Kidney Research and Clinical Practice, 41(5), pp.533~544 (2022), 대한신장학회[DOI]
156. Mak RH, "Wasting in chronic kidney disease", J Cachexia Sarcopenia Muscle, 2, pp.9~25 (2011)
157. Axelsson J, "Adipose tissue and inflammation in chronic kidney disease", Contrib Nephrol, 151, pp.165~174 (2006)
158. Cheung WW, "Inflammation and cachexia in chronic kidney disease", Pediatr Nephrol, 25, pp.711~724 (2010)
159. Ramalingam L, "The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance", Biochim Biophys Acta Mol Basis Dis, 1863, pp.1106~1114 (2017)
160. Powers SK, "The renin-angiotensin system and skeletal muscle", Exerc Sport Sci Rev, 46, pp.205~214 (2018)
161. Allen AM, "Localization and function of angiotensin AT1 receptors", Am J Hypertens, 13(1 Pt 2), pp.31S~38S (2000)
162. Linderman JR, "Distribution of angiotensin II receptor expression in the microcirculation of striated muscle", Microcirculation, 8, pp.275~281 (2001)
163. Santos RAS, "The ACE2", angiotensin-(1-7), Physiol Rev, pp.2018, 98[DOI]
164. Wright JT Jr, "Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease : results from the AASK trial", JAMA, 288, pp.2421~2431 (2002)
165. Lewis EJ, "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes", N Engl J Med, 345, pp.851~860 (2001)
166. Jafar TH, "Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data", Ann Intern Med, 135, pp.73~87 (2001)
167. Mann JF, "Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril : the HOPE randomized trial", Ann Intern Med, 134, pp.629~636 (2001)
168. Onder G, "Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women : an observational study", Lancet, 359, pp.926~930 (2002)
169. Hutcheon SD, "Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction : a randomised double blind placebo controlled trial", Heart, 88, pp.373~377 (2002)
170. Maggio M, "Relation of angiotensin-converting enzyme inhibitor treatment to insulin-like growth factor-1 serum levels in subjects >65 years of age(the InCHIANTI study)", Am J Cardiol, 97, pp.1525~1529 (2006)
171. LACE study group, "Effect of perindopril or leucine on physical performance in older people with sarcopenia : the LACE randomized controlled trial", J Cachexia Sarcopenia Muscle, 13, pp.858~871 (2022)
172. Burks TN, "Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia", Sci Transl Med, 3, pp.82ra37~ (2011)
173. Lin CH, "Losartan improves measures of activity, inflammation, and oxidative stress in older mice", Exp Gerontol, 58, pp.174~178 (2014)
174. Pahor M, "Effect of losartan and fish oil on plasma IL-6 and mobility in older persons. The ENRGISE pilot randomized clinical trial", J Gerontol A Biol Sci Med Sci, 74, pp.1612~1619 (2019)
175. Murphy KT, "Mas receptor activation slows tumor growth and attenuates muscle wasting in cancer", Cancer Res, 79, pp.706~719 (2019)
176. Levi A, "Elevated serum homocysteine is a predictor of accelerated decline in renal function and chronic kidney disease : a historical prospective study", Eur J Intern Med, 25, pp.951~955 (2014)
177. Bostom AG, "Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study", Arterioscler Thromb Vasc Biol, 17, pp.2554~2558 (1997)
178. Robinson K, "Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations", Circulation, 94, pp.2743~2748 (1996)
179. Swart KM, "Elevated homocysteine levels are associated with low muscle strength and functional limitations in older persons", J Nutr Health Aging, 17, pp.578~584 (2013)
180. Vidoni ML, "Relationship between homocysteine and muscle strength decline : the baltimore longitudinal study of aging", J Gerontol A Biol Sci Med Sci, 73, pp.546~551 (2018)
181. Ng TP, "Homocysteine, folate, vitamin B-12, and physical function in older adults : cross-sectional findings from the Singapore Longitudinal Ageing Study", Am J Clin Nutr, 96, pp.1362~1368 (2012)
182. van Schoor NM, "Cross-sectional and longitudinal association between homocysteine, vitamin B12 and physical performance in older persons", Eur J Clin Nutr, 66, pp.174~181 (2012)
183. Swart KM, "A randomized controlled trial to examine the effect of 2-year vitamin B12 and folic acid supplementation on physical performance, strength, and falling : additional findings from the B-PROOF study", Calcif Tissue Int, 98, pp.18~27 (2016)
184. Padayatty SJ, "Vitamin C as an antioxidant : evaluation of its role in disease prevention", J Am Coll Nutr, 22, pp.18~35 (2003)
185. Welch AA, "Cross-sectional associations between dietary antioxidant vitamins C, E and carotenoid intakes and sarcopenic indices in women aged 18-79 years", Calcif Tissue Int, 106, pp.331~342 (2020)
186. Konopacka M, "Antioxidant vitamins C, E and beta-carotene reduce DNA damage before as well as after gamma-ray irradiation of human lymphocytes in vitro", Mutat Res, 491, pp.1~7 (2001)
187. Poljšak B, "The antioxidant and pro-oxidant activity of vitamin C and trolox in vitro : a comparative study", J Appl Toxicol, 28, pp.183~188 (2008)
188. Liu X, "Co-encapsulation of vitamin C and β-carotene in liposomes : storage stability, antioxidant activity, and in vitro gastrointestinal digestion", Food Res Int, 136, pp.109587~ (2020)
189. Takahashi N, "Decreased plasma level of vitamin C in chronic kidney disease : comparison between diabetic and non-diabetic patients", Nephrol Dial Transplant, 26, pp.1252~1257 (2011)
190. Deicher R, "Vitamin C in chronic kidney disease and hemodialysis patients", Kidney Blood Press Res, 26, pp.100~106 (2003)
191. Molina P, "Vitamin D, a modulator of musculoskeletal health in chronic kidney disease", J Cachexia Sarcopenia Muscle, 8, pp.686~701 (2017)
192. Bauer JM, "Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study : a randomized, double-blind, placebo-controlled trial", J Am Med Dir Assoc, 16, pp.740~747 (2015)
193. Beaudart C, "The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power : a systematic review and meta-analysis of randomized controlled trials", J Clin Endocrinol Metab, 99, pp.4336~4345 (2014)
194. Murad MH, "The effect of vitamin D on falls : a systematic review and meta-analysis", J Clin Endocrinol Metab, 96, pp.2997~3006 (2011)
195. Nelsestuen GL, "The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin", J Biol Chem, 249, pp.6347~6350 (1974)
196. Stenflo J, "Vitamin K dependent modifications of glutamic acid residues in prothrombin", Proc Natl Acad Sci U S A, 71, pp.2730~2733 (1974)
197. Tew BY, "Vitamin K epoxide reductase regulation of androgen receptor activity", Oncotarget, 8, pp.13818~13831 (2017)
198. Holden RM, "Vitamins K and D status in stages 3-5 chronic kidney disease", Clin J Am Soc Nephrol, 5, pp.590~597 (2010)
199. Cranenburg EC, "Vitamin K intake and status are low in hemodialysis patients", Kidney Int, 82, pp.605~610 (2012)
200. Shea MK, "Vitamin K status and lower extremity function in older adults : the health aging and body composition study", J Gerontol A Biol Sci Med Sci, 71, pp.1348~1355 (2016)
201. van Ballegooijen AJ, "Vitamin K status and physical decline in older adults-The Longitudinal Aging Study Amsterdam", Maturitas, 113, pp.73~79 (2018)
202. Shea MK, "Reducing undercarboxylated osteocalcin with vitamin K supplementation does not promote lean tissue loss or fat gain over 3 years in older women and men : a randomized controlled trial", J Bone Miner Res, 32, pp.243~249 (2017)
203. Fulton RL, "Effect of vitamin K on vascular health and physical function in older people with vascular disease--a randomised controlled trial", J Nutr Health Aging, 20, pp.325~333 (2016)
204. Meng X, "Health benefits and molecular mechanisms of resveratrol : a narrative review", Foods, 9, pp.340~ (2020)
205. Harikumar KB, "Resveratrol : a multitargeted agent for age-associated chronic diseases", Cell Cycle, 7, pp.1020~1035 (2008)
206. Joseph AM, "Short-term caloric restriction, resveratrol, or combined treatment regimens initiated in late-life alter mitochondrial protein expression profiles in a fiber-type specific manner in aged animals", Exp Gerontol, 48, pp.858~868 (2013)
207. Bennett BT, "Effects of resveratrol on the recovery of muscle mass following disuse in the plantaris muscle of aged rats", PLoS One, 8, pp.e83518~ (2013)
208. Liao ZY, "The effect of exercise, resveratrol or their combination on Sarcopenia in aged rats via regulation of AMPK", Sirt1 pathway, 2017, pp.98, 177~183
209. Kan NW, "Effects of resveratrol supplementation and exercise training on exercise performance in middle-aged mice", Molecules, 21, pp.661~ (2016)
210. Muhammad MH, "Resveratrol and", or exercise training counteract aging-associated decline of physical endurance in aged mice; targeting mitochondrial biogenesis and function, 2018, pp.68, 681~688
211. Olesen J, "Exercise training, but not resveratrol, improves metabolic and inflammatory status in skeletal muscle of aged men", J Physiol, 592, pp.1873~1886 (2014)
212. Kojima M, "Ghrelin is a growth-hormone-releasing acylated peptide from stomach", Nature, 402, pp.656~660 (1999)
213. Hosoda H, "Purification and characterization of rat des-Gln14-Ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor", J Biol Chem, 275, pp.21995~22000 (2000)
214. Hosoda H, "Ghrelin and des-acyl ghrelin : two major forms of rat ghrelin peptide in gastrointestinal tissue", Biochem Biophys Res Commun, 279, pp.909~913 (2000)
215. Rodriguez Ayala E, "Associations between plasma ghrelin levels and body composition in end-stage renal disease : a longitudinal study", Nephrol Dial Transplant, 19, pp.421~426 (2004)
216. DeBoer MD, "Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia", Endocrinology, 148, pp.3004~3012 (2007)
217. DeBoer MD, "Ghrelin treatment of chronic kidney disease : improvements in lean body mass and cytokine profile", Endocrinology, 149, pp.827~835 (2008)
218. Miyazaki T, "Ghrelin level and body weight loss after esophagectomy for esophageal cancer", J Surg Res, 176, pp.74~78 (2012)
219. Argilés JM, "The potential of ghrelin in the treatment of cancer cachexia", Expert Opin Biol Ther, 13, pp.67~76 (2013)
220. Garcia JM, "Anamorelin for patients with cancer cachexia : an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials", Lancet Oncol, 16, pp.108~116 (2015)
221. Temel J, "Efficacy and safety results from a phase II study of anamorelin HCl, a ghrelin receptor agonist. NSCLC patients", J Cachexia Sarcopenia Muscle, 4, pp.295~343 (2013)
222. White HK, "Effects of an oral growth hormone secretagogue in older adults", J Clin Endocrinol Metab, 94, pp.1198~1206 (2009)
223. Alcalde-Estévez E, "Uraemic toxins impair skeletal muscle regeneration by inhibiting myoblast proliferation, reducing myogenic differentiation, and promoting muscular fibrosis", Sci Rep, 11, pp.512~ (2021)
224. Ohtsuki S, "Role of blood-brain barrier organic anion transporter 3(OAT3)in the efflux of indoxyl sulfate, a uremic toxin : its involvement in neurotransmitter metabolite clearance from the brain", J Neurochem, 83, pp.57~66 (2002)
225. Deguchi T, "Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney", Kidney Int, 61, pp.1760~1768 (2002)
226. Koppe L, "p-Cresyl sulfate promotes insulin resistance associated with CKD", J Am Soc Nephrol, 24, pp.88~99 (2013)
227. Sato E, "Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease", Sci Rep, 6, pp.36618~ (2016)
228. Niwa T, "Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease : experimental and clinical effects of oral sorbent AST-120", Ther Apher Dial, 15, pp.120~124 (2011)
229. Enoki Y, "Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1", Sci Rep, 6, pp.32084~ (2016)
230. Sallée M, "The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease", Toxins(Basel), 6, pp.934~949 (2014)
231. Watanabe I, "Activation of aryl hydrocarbon receptor mediates indoxyl sulfate-induced monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells", Circ J, 77, pp.224~230 (2013)
232. Enoki Y, "Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction", J Cachexia Sarcopenia Muscle, 8, pp.735~747 (2017)
233. Cha RH, "Effects of AST-120 on muscle health and quality of life in chronic kidney disease patients : results of RECOVERY study", J Cachexia Sarcopenia Muscle, 13, pp.397~408 (2022)

관련 논문AI추천